CardioVere enables personalized care through detection of non-clinical and clinical congestion non-invasively across all care settings, including home.
At CardioVere, our mission is to provide precise information early in the decompensation cycle to improve care for heart failure patients.
Lower Cost of Care
CardioVere’s parent company, ChemImage is a pioneer in Molecular Chemical Imaging (MCI). We have extensive experience in advanced surgical imaging and are the first company formed to bring MCI to materials analysis. As the only company with this level of expertise, we have been able to develop complex biological detection for healthcare optimization.
ChemImage-developed patents protect this peripheral edema monitoring device that will be highly differentiated and first to market. Patents are available for exclusive license under defined field of use. To learn more about ChemImage, visit us at chemimage.com.